111, Inc. (NASDAQ:YI - Get Free Report) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 23,700 shares, a growth of 66.9% from the January 15th total of 14,200 shares. Based on an average trading volume of 31,600 shares, the short-interest ratio is presently 0.8 days. Approximately 0.5% of the company's shares are sold short.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of 111 in a research report on Saturday, February 1st.
Read Our Latest Analysis on YI
111 Stock Up 4.1 %
Shares of YI traded up $0.30 during trading hours on Friday, reaching $7.65. The stock had a trading volume of 31,058 shares, compared to its average volume of 48,665. 111 has a 52 week low of $4.14 and a 52 week high of $15.80. The firm has a 50-day moving average of $6.41 and a 200 day moving average of $7.46. The company has a market cap of $65.41 million, a P/E ratio of -1.91 and a beta of 0.41.
111 (NASDAQ:YI - Get Free Report) last released its earnings results on Wednesday, November 27th. The company reported ($0.20) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On 111
Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after buying an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 during the 4th quarter worth about $245,000. Finally, FIL Ltd acquired a new position in shares of 111 during the 4th quarter worth about $450,000. Institutional investors own 21.32% of the company's stock.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
See Also
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
